The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
Bloomberg
Jielun Zhu, the former head of Asia healthcare investment banking at Jefferies Financial Group Inc., is joining I-Mab Biopharma Co. as chief financial officer, people familiar with the matter said.
In his new Hong Kong-based role, Zhu will focus on helping I-Mab with a planned initial public offering in the city, according to the people.
The Chinese biotech firm aims to list as soon as the fourth quarter, the people said, asking not to be identified because the details are private.
I-Mab has attracted capital from some China’s most active private equity investors including Hony Capital, Hopu Investment Management and Hillhouse Capital.
Hony led its $220 million Series C fundraising this year, while C-Bridge Capital Partners and Shanghai Tasly Pharmaceutical Co. led a $150 million round in 2017.
Zhu’s broader responsibilities at I-Mab will include
corporate finance, strategy, business development, licensing and mergers and acquisitions, the people said. Zhu was a managing director at Jefferies since December 2015.